Former Schering-Plough Reps Due Overtime

September 2011
Pharmaceutical Representative;Sep2011, Vol. 41 Issue 9, p9
The article discusses a court decision concerning the overtime payments due for the former sales representatives of Schering-Plough Corp.


Related Articles

  • Wearing Pager Off Duty Is Not Compensable. Moldover, Judith Ann // HR Magazine;Oct2006, Vol. 51 Issue 10, p119 

    The article discusses the ruling of the 6th U.S. Circuit Court of Appeals on the case, Adair v. Charter County of Wayne, that off-duty police officers who were required to carry pagers and leave them turned on, and were also required to remain within a specified geographical area, were not...

  • A commitment.  // Northern New Jersey Business;3/22/95, Vol. 3 Issue 6, p3 

    Reports that Schering-Plough Corp. dedicated new biotechnology clinical production facilities in Union and in Lucerne, Switzerland. Company operations.

  • Schering-Plough del Caribe launches `Sharing is Caring' campaign.  // Caribbean Business;10/9/1997, Vol. 25 Issue 40, p20 

    Reports on the `Sharing is Caring' community service program created by Schering-Plough del Caribe, a leading asthma and allergy medication manufacturer. Background on the phases of the program; Comments from Marisa Blay director of Proyecto Amor company.

  • Forecast service provides UV index.  // Dermatology Times;Jul95, Vol. 16 Issue 7, p58 

    Reports on Schering-Plough's SunCast UV Forecast Service which provides ultra-violet (UV) index for more than one time period per day.

  • Schering-Plough rescinds `at-risk' pay plan. Laabs, Jennifer J. // Workforce (10928332);Sep97, Vol. 76 Issue 9, p23 

    Announces that Schering-Plough Corp. has decided to discontinue plans to phase in its new performance-based compensation. Discontent of workers during a `dry run'; Reduction of employees' base pay; Miscommunication on advantages.

  • Melanoma treatment recommended.  // Dermatology Times;Sep95, Vol. 16 Issue 9, p3 

    Reports that the US Food and Drug Administration's Oncological Drugs Advisory Committee has approved Schering's interferon alfa-2b for the treatment of malignant melanoma.

  • Schering-Plough launches $80,000 campaign. Rodriguez, Sandra D. // Caribbean Business;10/7/1993, Vol. 21 Issue 40, p46 

    Reports on Schering-Plough del Caribe Inc.'s launching of an institutional campaign to enhance its image in Puerto Rico and to promote preventive medicine. Use of public relations and promotions; Sponsorship of activities with doctors, nurses, health associations and schools; `A World of...

  • Schering plows into fertile turf. Warner, Bernhard // Brandweek;10/14/96, Vol. 37 Issue 39, p1 

    Reports on Schering-Plough Healthcare Products' negotiation with a cadre of national home centers and nursery retailers to bolster its in-store presence. National Gardening Association's endorsement of the company's effort to target its marketing to gardening enthusiasts in the United States;...

  • CDER Division of Drug marketing finds Schering MDI promo misleading. Dickinson, James G. // Medical Marketing & Media;Jul97, Vol. 32 Issue 7, p29 

    Focuses on CDER Division of Drug Marketing, Advertising and Communications' lawyer Joan Jankin's notice-of-violation letter for a product launch press release for Schering's Proventil-HFA. Hankin's argument that the company added an additional clinical claim that was similar to the one objected...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics